AC Immune (NASDAQ:ACIU) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Wednesday.
A number of other brokerages also recently commented on ACIU. BidaskClub raised shares of AC Immune from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 26th. Zacks Investment Research raised shares of AC Immune from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. Credit Suisse Group downgraded shares of AC Immune from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $18.00 to $14.00 in a research note on Friday, March 23rd. Finally, HC Wainwright began coverage on shares of AC Immune in a research note on Thursday, April 5th. They issued a “buy” rating and a $18.00 price objective for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $14.00.
Shares of NASDAQ:ACIU opened at $10.46 on Wednesday. AC Immune has a 52 week low of $6.03 and a 52 week high of $13.91.
AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Tuesday, March 20th. The company reported $0.06 EPS for the quarter. The company had revenue of $16.64 million during the quarter. AC Immune had a negative net margin of 147.54% and a negative return on equity of 24.43%. analysts forecast that AC Immune will post -1.06 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN purchased a new position in AC Immune in the third quarter worth $111,000. Renaissance Technologies LLC purchased a new position in AC Immune in the fourth quarter worth $143,000. Finally, Tekla Capital Management LLC grew its holdings in AC Immune by 319.9% in the fourth quarter. Tekla Capital Management LLC now owns 171,813 shares of the company’s stock worth $2,199,000 after purchasing an additional 130,894 shares during the last quarter. 19.47% of the stock is currently owned by institutional investors and hedge funds.
About AC Immune
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.